William Blair analyst Matt Phipps has reiterated their bullish stance on GMAB stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Phipps has given his Buy rating due to a combination of factors that highlight Genmab’s strong financial performance and promising pipeline developments. The company reported impressive second-quarter results, surpassing both internal and consensus revenue estimates, driven by robust royalties from Darzalex and Kesimpta, as well as significant sales growth of Epkinly. This financial strength has led to an upward revision of the full-year revenue guidance, indicating confidence in continued performance.
Furthermore, Genmab’s late-stage pipeline shows considerable potential, with three Phase III studies for Rina-S set to commence by the end of the year and an anticipated approval decision for Epkinly’s label expansion in follicular lymphoma. The positive results from the EPCORE FL-1 study further support this outlook. These developments suggest a strong trajectory for long-term revenue growth, reinforcing the Buy rating as the company is well-positioned to capitalize on its strategic advancements.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $24.50 price target.